Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (4): 324-329.DOI: 10.3969/j.issn.1673-8640.2024.04.003
Previous Articles Next Articles
LI Yue, TENG Xiaoyan, DING Siying, HU Liuping, DU Yuzhen()
Received:
2023-10-25
Revised:
2023-12-22
Online:
2024-04-30
Published:
2024-05-07
CLC Number:
LI Yue, TENG Xiaoyan, DING Siying, HU Liuping, DU Yuzhen. Predictive role of neutrophil-to-lymphocyte ratio for distant metastasis in solid tumor patients[J]. Laboratory Medicine, 2024, 39(4): 324-329.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.04.003
组别 | 例数 | 性别 | 年龄/岁 | TNM分期 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/ [例(%)] | 女/ [例(%)] | Ⅰ期/ [例(%)] | Ⅱ期/ [例(%)] | Ⅲ期/ [例(%)] | Ⅳ期/ [例(%)] | |||||||||||
无远隔转移组 | 104 | 45(17.38) | 59(22.78) | 64.85±11.63 | 26(10.03) | 31(11.97) | 47(18.15) | |||||||||
远隔转移组 | 155 | 97(37.45) | 58(22.39) | 65.23±11.24 | 155(59.85) | |||||||||||
统计值 | 2.834 | -0.374 | ||||||||||||||
P值 | 0.005 | 0.709 | ||||||||||||||
组别 | WBC计数/(×109/L) | RBC计数/(×1012/L) | Hb/(g·L-1) | HCT/% | PLT计数/(×109/L) | |||||||||||
无远隔转移组 | 5.44(4.59~7.01) | 4.07±0.74 | 123.43±20.39 | 37.15±5.73 | 196.50(149.50~258.25) | |||||||||||
远隔转移组 | 6.53(4.97~8.53) | 3.76±0.67 | 111.83±20.17 | 34.15±5.58 | 195.00(149.00~266.00) | |||||||||||
统计值 | -3.302 | 3.454 | 4.515 | 4.187 | -0.078 | |||||||||||
P值 | 0.001 | 0.001 | 0.001 | 0.001 | 0.938 | |||||||||||
组别 | NEUT#/(×109/L) | LYMPH#/(×109/L) | MO#/(×109/L) | EO#/(×109/L) | ||||||||||||
无远隔转移组 | 3.12(2.52~4.33) | 1.61±0.65 | 0.44(0.35~0.56) | 0.10(0.04~0.19) | ||||||||||||
远隔转移组 | 4.46(3.09~6.46) | 1.29±0.54 | 0.51(0.34~0.70) | 0.09(0.04~0.18) | ||||||||||||
统计值 | -5.181 | 4.739 | -2.010 | -0.688 | ||||||||||||
P值 | <0.001 | <0.001 | 0.044 | 0.491 | ||||||||||||
组别 | BASO#/(×109/L) | NLR | PLR | LMR | ||||||||||||
无远隔转移组 | 0.03(0.02~0.04) | 1.98(1.48~2.68) | 109.15(71.29~160.48) | 3.43(2.50~4.85) | ||||||||||||
远隔转移组 | 0.02(0.01~0.03) | 4.11(2.51~5.96) | 141.11(91.89~201.57) | 2.23(1.58~3.65) | ||||||||||||
统计值 | -1.794 | -7.471 | -2.852 | -5.423 | ||||||||||||
P值 | 0.073 | <0.001 | 0.004 | <0.001 |
组别 | 例数 | 性别 | 年龄/岁 | TNM分期 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/ [例(%)] | 女/ [例(%)] | Ⅰ期/ [例(%)] | Ⅱ期/ [例(%)] | Ⅲ期/ [例(%)] | Ⅳ期/ [例(%)] | |||||||||||
无远隔转移组 | 104 | 45(17.38) | 59(22.78) | 64.85±11.63 | 26(10.03) | 31(11.97) | 47(18.15) | |||||||||
远隔转移组 | 155 | 97(37.45) | 58(22.39) | 65.23±11.24 | 155(59.85) | |||||||||||
统计值 | 2.834 | -0.374 | ||||||||||||||
P值 | 0.005 | 0.709 | ||||||||||||||
组别 | WBC计数/(×109/L) | RBC计数/(×1012/L) | Hb/(g·L-1) | HCT/% | PLT计数/(×109/L) | |||||||||||
无远隔转移组 | 5.44(4.59~7.01) | 4.07±0.74 | 123.43±20.39 | 37.15±5.73 | 196.50(149.50~258.25) | |||||||||||
远隔转移组 | 6.53(4.97~8.53) | 3.76±0.67 | 111.83±20.17 | 34.15±5.58 | 195.00(149.00~266.00) | |||||||||||
统计值 | -3.302 | 3.454 | 4.515 | 4.187 | -0.078 | |||||||||||
P值 | 0.001 | 0.001 | 0.001 | 0.001 | 0.938 | |||||||||||
组别 | NEUT#/(×109/L) | LYMPH#/(×109/L) | MO#/(×109/L) | EO#/(×109/L) | ||||||||||||
无远隔转移组 | 3.12(2.52~4.33) | 1.61±0.65 | 0.44(0.35~0.56) | 0.10(0.04~0.19) | ||||||||||||
远隔转移组 | 4.46(3.09~6.46) | 1.29±0.54 | 0.51(0.34~0.70) | 0.09(0.04~0.18) | ||||||||||||
统计值 | -5.181 | 4.739 | -2.010 | -0.688 | ||||||||||||
P值 | <0.001 | <0.001 | 0.044 | 0.491 | ||||||||||||
组别 | BASO#/(×109/L) | NLR | PLR | LMR | ||||||||||||
无远隔转移组 | 0.03(0.02~0.04) | 1.98(1.48~2.68) | 109.15(71.29~160.48) | 3.43(2.50~4.85) | ||||||||||||
远隔转移组 | 0.02(0.01~0.03) | 4.11(2.51~5.96) | 141.11(91.89~201.57) | 2.23(1.58~3.65) | ||||||||||||
统计值 | -1.794 | -7.471 | -2.852 | -5.423 | ||||||||||||
P值 | 0.073 | <0.001 | 0.004 | <0.001 |
项目 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
OR值(95%CI) | P值 | OR值(95%CI) | P值 | ||
性别 | 2.193(1.322~3.638) | 0.002 | 1.695(0.976~2.943) | 0.052 | |
WBC计数 | 1.139(1.041~1.247) | 0.005 | 0.619(0.196~1.960) | 0.258 | |
RBC计数 | 0.535(0.369~0.774) | 0.001 | 0.992(0.408~2.413) | 0.921 | |
Hb | 0.971(0.958~0.985) | <0.001 | 0.939(0.878~1.005) | 0.053 | |
HCT | 0.908(0.865~0.953) | <0.001 | 1.173(0.882~1.559) | 0.246 | |
PLT计数 | 1.001(0.998~1.004) | 0.525 | |||
NEUT# | 1.271(1.124~1.437) | <0.001 | 2.090(0.630~6.932) | 0.128 | |
LYMPH# | 0.375(0.242~0.580) | <0.001 | 0.446(0.122~1.629) | 0.361 | |
MO# | 3.481(1.276~9.492) | 0.015 | 6.310(0.886~44.939) | 0.071 | |
EO# | 1.380(0.542~3.515) | 0.500 | |||
BASO# | 0.000(0.000~0.306) | 0.300 | |||
NLR | 1.510(1.289~1.769) | <0.001 | 1.488(1.250~1.771) | <0.001 | |
PLR | 1.003(1.000~1.006) | 0.025 | 0.999(0.996~1.002) | 0.667 | |
LMR | 0.789(0.677~0.921) | 0.003 | 0.934(0.810~1.077) | 0.347 |
项目 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
OR值(95%CI) | P值 | OR值(95%CI) | P值 | ||
性别 | 2.193(1.322~3.638) | 0.002 | 1.695(0.976~2.943) | 0.052 | |
WBC计数 | 1.139(1.041~1.247) | 0.005 | 0.619(0.196~1.960) | 0.258 | |
RBC计数 | 0.535(0.369~0.774) | 0.001 | 0.992(0.408~2.413) | 0.921 | |
Hb | 0.971(0.958~0.985) | <0.001 | 0.939(0.878~1.005) | 0.053 | |
HCT | 0.908(0.865~0.953) | <0.001 | 1.173(0.882~1.559) | 0.246 | |
PLT计数 | 1.001(0.998~1.004) | 0.525 | |||
NEUT# | 1.271(1.124~1.437) | <0.001 | 2.090(0.630~6.932) | 0.128 | |
LYMPH# | 0.375(0.242~0.580) | <0.001 | 0.446(0.122~1.629) | 0.361 | |
MO# | 3.481(1.276~9.492) | 0.015 | 6.310(0.886~44.939) | 0.071 | |
EO# | 1.380(0.542~3.515) | 0.500 | |||
BASO# | 0.000(0.000~0.306) | 0.300 | |||
NLR | 1.510(1.289~1.769) | <0.001 | 1.488(1.250~1.771) | <0.001 | |
PLR | 1.003(1.000~1.006) | 0.025 | 0.999(0.996~1.002) | 0.667 | |
LMR | 0.789(0.677~0.921) | 0.003 | 0.934(0.810~1.077) | 0.347 |
组别 | 例数 | 辅助性T细胞/(×106/L) | 细胞毒性T细胞/(×106/L) | B细胞/(×106/L) | ||
---|---|---|---|---|---|---|
高NLR组 | 159 | 104.98(60.56~170.98) | 321.07±200.52 | 476.52(311.43~704.18) | ||
低NLR组 | 100 | 687.60(525.39~1 015.92)* | 462.93±201.44* | 152.99(68.78~321.52)* | ||
统计值 | -5.494 | -4.915 | -3.339 | |||
P值 | <0.001 | <0.001 | 0.001 | |||
组别 | NK细胞/(×106/L) | 双阳性T细胞/(×106/L) | 双阴性T细胞/(×106/L) | |||
高NLR组 | 236.16±177.59 | 2.53(0.90~4.19) | 27.72(13.72~51.28) | |||
低NLR组 | 296.58±211.93* | 4.20(1.64~10.00) | 51.33(29.80~68.99)* | |||
统计值 | -2.211 | -0.419 | -4.758 | |||
P值 | 0.028 | 0.676 | <0.001 |
组别 | 例数 | 辅助性T细胞/(×106/L) | 细胞毒性T细胞/(×106/L) | B细胞/(×106/L) | ||
---|---|---|---|---|---|---|
高NLR组 | 159 | 104.98(60.56~170.98) | 321.07±200.52 | 476.52(311.43~704.18) | ||
低NLR组 | 100 | 687.60(525.39~1 015.92)* | 462.93±201.44* | 152.99(68.78~321.52)* | ||
统计值 | -5.494 | -4.915 | -3.339 | |||
P值 | <0.001 | <0.001 | 0.001 | |||
组别 | NK细胞/(×106/L) | 双阳性T细胞/(×106/L) | 双阴性T细胞/(×106/L) | |||
高NLR组 | 236.16±177.59 | 2.53(0.90~4.19) | 27.72(13.72~51.28) | |||
低NLR组 | 296.58±211.93* | 4.20(1.64~10.00) | 51.33(29.80~68.99)* | |||
统计值 | -2.211 | -0.419 | -4.758 | |||
P值 | 0.028 | 0.676 | <0.001 |
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
DOI URL |
[2] |
HUANG C H, LEI K F. Cell marathon:long-distance cell migration and metastasis-associated gene analysis using a folding paper system[J]. Lab Chip, 2022, 22(20):3827-3836.
DOI URL |
[3] |
KIM H S, EL-SERAG H B. The epidemiology of hepatocellular carcinoma in the USA[J]. Curr Gastroenterol Rep, 2019, 21(4):17.
DOI |
[4] |
BOZKAYA Y, DEMIRCI N S, KURTIPEK A, et al. Clinicopathological and prognostic characteristics in patients with AFP-secreting gastric carcinoma[J]. Mol Clin Oncol, 2017, 7(2):267-274.
DOI PMID |
[5] |
AL-SAWAT A, BEA J H, HAN S R, et al. Use of ascitic CEA levels as a predictive value for distant metastasis in high-risk stage Ⅱ and Ⅲ colorectal cancer[J]. Int J Colorectal Dis, 2022, 37(2):365-372.
DOI |
[6] |
NUMATA T, ENDO T, YANAI H, et al. Serum CEA and CYFRA levels in ALK-rearranged NSCLC patients:correlation with distant metastasis[J]. In Vivo, 2020, 34(4):2095-2100.
DOI URL |
[7] |
JIANG W, BAI W, LI J, et al. Leukemia inhibitory factor is a novel biomarker to predict lymph node and distant metastasis in pancreatic cancer[J]. Int J Cancer, 2021, 148(4):1006-1013.
DOI URL |
[8] | TONG J, JIANG W, ZHANG X, et al. CCL22 and CCL26 are potential biomarkers for predicting distant metastasis in thyroid carcinoma[J]. J Int Med Res, 2022, 50(12):3000605221139555. |
[9] |
HUAI Q, LUO C Y, SONG P, et al. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy[J]. Cancer sci, 2023, 114(12):4484-4498.
DOI URL |
[10] |
LIU H L, FENG X, TANG M M, et al. Prognostic significance of preoperative lymphocyte to monocyte ratio in patients with signet ring gastric cancer[J]. World J Gastrointest Surg, 2023, 15(8):1673-1683.
DOI URL |
[11] | CHEN Y, SUN J, HU D, et al. Predictive value of pretreatment lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio in the survival of nasopharyngeal carcinoma patients[J]. Cancer Manag Res, 2021,13:8767-8779. |
[12] |
DE B, LUDMIR E B, MESSICK C A, et al. Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma[J]. J Gastrointest Oncol, 2021, 12(5):2412-2422.
DOI PMID |
[13] |
ITO Y, ONODA N, KIHARA M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in differentiated thyroid carcinoma having distant metastasis:a comparison with thyroglobulin-doubling rate and tumor volume-doubling rate[J]. In Vivo, 2021, 35(2):1125-1132.
DOI URL |
[14] | HUNG H C, LEE J C, WANG Y C, et al. Response prediction in immune checkpoint inhibitor immunotherapy for advanced hepatocellular carcinoma[J]. Cancers(Basel), 2021, 13(7):1607. |
[15] | ALBRENGUES J, SHIELDS M A, NG D, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice[J]. Science, 2018, 361(6409):eaao4227. |
[16] |
BALKWILL F, MANTOVANI A. Inflammation and cancer:back to virchow?[J]. Lancet, 2001, 357(9255):539-545.
DOI URL |
[17] |
COFFELT S B, KERSTEN K, DOORNEBAL C W, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis[J]. Nature, 2015, 522(7556):345-348.
DOI |
[18] |
LOI S, SIRTAINE N, PIETTE F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase Ⅲ randomized adjuvant breast cancer trial in node-positiveb breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy:BIG 02-98[J]. J Clin Oncol, 2013, 31(7):860-867.
DOI URL |
[19] |
KUMARI R, HOSSEINI E S, WARRINGTON K E, et al. Butyrophilins:dynamic regulators of protective T cell immunity in cancer[J]. Int J Mol Sci, 2023, 24(10):8722.
DOI URL |
[20] |
LI P, LI F, ZHANG Y, et al. Metabolic diversity of tumor-infiltrating T cells as target for anti-immune therapeutics[J]. Cancer Immunol Immunother, 2023, 72(11):3453-3460.
DOI PMID |
[21] | WU Z, ZHENG Y, SHENG J, et al. CD3+CD4-CD8-(double-negative) T cells in inflammation,immune disorders and cancer[J]. Frontiers in Immunology, 2022,13:816005. |
[22] |
RUDDELL A, HARRELL M I, FURUYA M, et al. B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma[J]. Neoplasia, 2011, 13(8):748-757.
DOI PMID |
[23] |
MAKITA K, HAMAMOTO Y, KANZAKI H, et al. An easy tool to predict survival in patients with bone metastatic lung cancer treated with palliative radiotherapy[J]. Thorac Cancer, 2023, 14(19):1795-1801.
DOI URL |
[24] |
ZHANG X, WANG X, LI W, et al. Predictive value of neutrophil-to-lymphocyte ratio for distant metastasis in gastric cancer patients[J]. Sci Rep, 2022, 12(1):10269.
DOI PMID |
[25] |
WIRA WIGUNA I G W, INDRANI REMITHA N P S, SADVIKA I G A S, et al. Pretreatment leukocyte count ratios as metastatic predictive factors in luminal type breast cancer[J]. Asian Pac J Cancer Prev, 2022, 23(5):1595-1601.
DOI URL |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||